AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$AORT

Mackin James P sold $2.0M of AORT

Mackin James P (President & CEO) sold 70,000 shares of ARTIVION, INC. (AORT) at $28.96 ($2.03M total) on 2026-08-19.

Original reporting
SEC EDGAR · Mackin James P
Published Aug 20, 2026, 6:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 6:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AORT
Bearish
medium confidence
Mentioned
$AORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTBearishLow
01

Why it matters

The disclosed sale represents a fresh data point for traders assessing insider sentiment and may influence short‑term price action.

02

Market read

Direct relevance to Artivion shareholders; indirect relevance to biotech sector investors monitoring insider activity.

03

What to watch

Potential tax planning or liquidity needs for the executive; no immediate change in company operations.

Relevance 6/10Novelty 7/10Timing: filed today

Background

Form 4 filings provide the first public record of insider transactions, offering transparency into executive holdings.

Company-level read

Ticker impact

$AORTBearishMedium confidence
Context

SEC Form 4 disclosed President & CEO Mackin James P sold 70,000 shares of Artivion at $28.96 each, total $2.03M.

Expected impact

modest short‑term downside pressure

Evidence & confidence

A $2M sale by a top executive is material for a mid‑cap biotech, but the size relative to total float is limited.

Market effects

Sector

May raise concerns for biotech sector insiders and could prompt scrutiny of other executive holdings.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond Artivion shareholders.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Company
    Artivion, Inc.

    Biotech firm developing medical devices and therapies.

  • Executive
    Mackin James P

    President & CEO of Artivion.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AORT insider trading history →

Related articles

$AORTMed

Artivion: Q3 Earnings Snapshot

Artivion, Inc. (AORT) reported a Q3 loss of $7.9 million, down from a profit last year. Adjusted EPS was 8 cents. Revenue was $123.8 million. The company expects Q4 revenue between $484M and $492M. Shares have fallen 45% YTD and 46% over 12 months.

finance.yahoo.com
$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Third Quarter 2026 F

SEC EDGAR 8-K
$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.

prnewswire.com
$AORTHigh

Why is Artivion stock rallying today?

Artivion (AORT) stock rose 4.7% after Jefferies initiated coverage with a Buy rating and $31 price target, citing near-term product catalysts and growth potential. The firm expects 39% upside from the prior close, highlighting product launches and margin accretion. Artivion's Q3 2026 earnings report is due soon, adding to near-term interest.

investing.com
$AORTMed

Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’

Artivion Inc (NYSE:AORT) shares rose 4.2% after Jefferies initiated coverage with a Buy rating and $31 price target. The firm cited the company's expanding product pipeline, expected double-digit revenue growth, and expanding profit margins. Jefferies forecasts $547M and $617M in revenue for 2027 and 2028, respectively, above consensus. The stock is seen as undervalued relative to peers, offering an attractive entry point ahead of commercial catalysts.

investing.com